Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I Study of RGX-202-01, a Small Molecule Inhibitor of the Creatine Transporter SLC6a8, With or Without FOLFIRI, in Patients With Advanced Gastrointestinal Malignancies With Select Expansion Cohorts

Summary

The purpose of this phase I study is to evaluate the safety of RGX-202-01 alone or in combination with FOLFIRI in patients with gastrointestinal cancer, including pancreatic cancer.

General Information

NCT#: NCT03597581
Study ID: RGX-202-001
Trial Phase: Phase I

Trial Sponsor: Rgenix, Inc.
Therapies Used in This Trial: Fluorouracil, Irinotecan, Leucovorin, FOLFIRI, RGX-202-01

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search